C. Logothetis

发表

Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database

Christopher P. Filson, D. Nieboer, E. Steyerberg, 2021, European urology open science.

Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acet

C. Parker, H. Scher, J. Bono, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetat

C. Parker, H. Scher, M. Fleisher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identi ﬁ cation of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer

P. Corn, D. Hawke, R. Satcher, 2015 .

Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer.

M. Kogevinas, R. Eeles, G. Giles, 2022, European urology oncology.

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.

M. Sydes, M. Gleave, R. Eeles, 2022, European urology.

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative

D. Nieboer, B. Trock, P. Dasgupta, 2022, European urology open science.

The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression

I. Grypari, P. Troncoso, V. Tzelepi, 2021, Medicine.

Putting Precision Medicine in Prostate Cancer into Practice: Are We There Yet?

P. Pilié, C. Logothetis, 2022, European Urology.

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Macie J. Rubin, M. Rubin, M. Sydes, 2023, European journal of cancer.

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, H. Scher, E. Small, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

M. Morris, A. Armstrong, C. Higano, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Using the Movember Foundation’s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function—a retrospective study in low-risk prostate cancer patients

Catherine Han Lin, M. Kattan, D. Nieboer, 2021, Translational Andrology and Urology.

A first step towards a global nomogram to predict disease progression for men on active surveillance

Catherine Han Lin, M. Kattan, D. Nieboer, 2020, Translational andrology and urology.

Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy.

H. Scher, C. Sternberg, K. Fizazi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

M. Sydes, M. Gleave, R. Eeles, 2022, European Urology.

1098 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE III STUDY

H. Scher, J. Bono, Robert J. Jones, 2011 .